Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced

Science 19 September 1986:
Vol. 233. no. 4770, pp. 1318 - 1321
DOI: 10.1126/science.3489291

Articles

Science, Vol 233, Issue 4770, 1318-1321
Copyright © 1986 by American Association for the Advancement of Science


articles

A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes

SA Rosenberg, P Spiess, and R Lafreniere

The adoptive transfer of tumor-infiltrating lymphocytes (TIL) expanded in interleukin-2 (IL-2) to mice bearing micrometastases from various types of tumors showed that TIL are 50 to 100 times more effective in their therapeutic potency than are lymphokine-activated killer (LAK) cells. Therefore the use of TIL was explored for the treatment of mice with large pulmonary and hepatic metastatic tumors that do not respond to LAK cell therapy. Although treatment of animals with TIL alone or cyclophosphamide alone had little impact, these two modalities together mediated the elimination of large metastatic cancer deposits in the liver and lung. The combination of TIL and cyclophosphamide was further potentiated by the simultaneous administration of IL-2. With the combination of cyclophosphamide, TIL, and IL-2, 100% of mice (n = 12) bearing the MC-38 colon adenocarcinoma were cured of advanced hepatic metastases, and up to 50% of mice were cured of advanced pulmonary metastases. Techniques have been developed to isolate TIL from human tumors. These experiments provide a rationale for the use of TIL in the treatment of humans with advanced cancer.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Effector/Memory but Not Naive Regulatory T Cells Are Responsible for the Loss of Concomitant Tumor Immunity.
Y.-C. Lin, L.-Y. Chang, C.-T. Huang, H.-M. Peng, A. Dutta, T.-C. Chen, C.-T. Yeh, and C.-Y. Lin (2009)
J. Immunol. 182, 6095-6104
   Abstract »    Full Text »    PDF »
Large-Scale Production and Characterization of Novel CD4+ Cytotoxic T Cells with Broad Tumor Specificity for Immunotherapy.
C. Jursik, M. Prchal, R. Grillari-Voglauer, K. Drbal, E. Fuertbauer, H. Jungfer, W. H. Albert, E. Steinhuber, T. Hemetsberger, J. Grillari, et al. (2009)
Mol. Cancer Res. 7, 339-353
   Abstract »    Full Text »    PDF »
Serotonin Regulates Macrophage-Mediated Angiogenesis in a Mouse Model of Colon Cancer Allografts.
A. Nocito, F. Dahm, W. Jochum, J. H. Jang, P. Georgiev, M. Bader, R. Graf, and P.-A. Clavien (2008)
Cancer Res. 68, 5152-5158
   Abstract »    Full Text »    PDF »
Tumor-Induced Immune Suppression of In vivo Effector T-Cell Priming Is Mediated by the B7-H1/PD-1 Axis and Transforming Growth Factor {beta}.
S. Wei, A. B. Shreiner, N. Takeshita, L. Chen, W. Zou, and A. E. Chang (2008)
Cancer Res. 68, 5432-5438
   Abstract »    Full Text »    PDF »
Interleukin 21 Enhances Antibody-Mediated Tumor Rejection.
M. J. Smyth, M. W.L. Teng, J. Sharkey, J. A. Westwood, N. M. Haynes, H. Yagita, K. Takeda, P. V. Sivakumar, and M. H. Kershaw (2008)
Cancer Res. 68, 3019-3025
   Abstract »    Full Text »    PDF »
Mouse Dendritic-Endothelial Cell Hybrids and 4-1BB Costimulation Elicit Antitumor Effects Mediated by Broad Antiangiogenic Immunity.
E. Ko, W. Luo, L. Peng, X. Wang, and S. Ferrone (2007)
Cancer Res. 67, 7875-7884
   Abstract »    Full Text »    PDF »
Adoptive transfer of tumor-primed, in vitro activated, CD4+ T effector cells (TEs) combined with CD8+ TEs provides intratumoral TE proliferation and synergistic antitumor response.
L.-X. Wang, S. Shu, M. L. Disis, and G. E. Plautz (2007)
Blood 109, 4865-4876
   Abstract »    Full Text »    PDF »
CD8+ T-Cell Content in Diagnostic Lymph Nodes Measured by Flow Cytometry Is a Predictor of Survival in Follicular Lymphoma.
B. E. Wahlin, B. Sander, B. Christensson, and E. Kimby (2007)
Clin. Cancer Res. 13, 388-397
   Abstract »    Full Text »    PDF »
Inhibition of Human Tumor-Infiltrating Lymphocyte Effector Functions by the Homophilic Carcinoembryonic Cell Adhesion Molecule 1 Interactions.
G. Markel, R. Seidman, N. Stern, T. Cohen-Sinai, O. Izhaki, G. Katz, M. Besser, A. J. Treves, R. S. Blumberg, R. Loewenthal, et al. (2006)
J. Immunol. 177, 6062-6071
   Abstract »    Full Text »    PDF »
Gene Transfer of Tumor-Reactive TCR Confers Both High Avidity and Tumor Reactivity to Nonreactive Peripheral Blood Mononuclear Cells and Tumor-Infiltrating Lymphocytes.
L. A. Johnson, B. Heemskerk, D. J. Powell Jr., C. J. Cohen, R. A. Morgan, M. E. Dudley, P. F. Robbins, and S. A. Rosenberg (2006)
J. Immunol. 177, 6548-6559
   Abstract »    Full Text »    PDF »
A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer..
M. H. Kershaw, J. A. Westwood, L. L. Parker, G. Wang, Z. Eshhar, S. A. Mavroukakis, D. E. White, J. R. Wunderlich, S. Canevari, L. Rogers-Freezer, et al. (2006)
Clin. Cancer Res. 12, 6106-6115
   Abstract »    Full Text »    PDF »
Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes.
R. A. Morgan, M. E. Dudley, J. R. Wunderlich, M. S. Hughes, J. C. Yang, R. M. Sherry, R. E. Royal, S. L. Topalian, U. S. Kammula, N. P. Restifo, et al. (2006)
Science 314, 126-129
   Abstract »    Full Text »    PDF »
Combination of Vaccination and Chimeric Receptor Expressing T Cells Provides Improved Active Therapy of Tumors.
H.-R. Jiang, D. E. Gilham, K. Mulryan, N. Kirillova, R. E. Hawkins, and P. L. Stern (2006)
J. Immunol. 177, 4288-4298
   Abstract »    Full Text »    PDF »
Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation.
P. J. Amrolia, G. Muccioli-Casadei, H. Huls, S. Adams, A. Durett, A. Gee, E. Yvon, H. Weiss, M. Cobbold, H. B. Gaspar, et al. (2006)
Blood 108, 1797-1808
   Abstract »    Full Text »    PDF »
Ex vivo Culture with Interleukin (IL)-12 Improves CD8+ T-Cell Adoptive Immunotherapy for Murine Leukemia Independent of IL-18 or IFN-{gamma} but Requires Perforin..
J. N. MacGregor, Q. Li, A. E. Chang, T. M. Braun, D. P.M. Hughes, and K. T. McDonagh (2006)
Cancer Res. 66, 4913-4921
   Abstract »    Full Text »    PDF »
Renal Cancer Treatment with Low Levels of Mixed Chimerism Induced by Nonmyeloablative Regimen Using Cyclophosphamide in Mice.
M. Harano, M. Eto, T. Iwai, K. Tatsugami, K. Kiyoshima, Y. Kamiryo, M. Tsuneyoshi, Y. Yoshikai, and S. Naito (2005)
Cancer Res. 65, 10032-10040
   Abstract »    Full Text »    PDF »
Adoptive transfer of gene-engineered CD4+ helper T cells induces potent primary and secondary tumor rejection.
M. Moeller, N. M. Haynes, M. H. Kershaw, J. T. Jackson, M. W. L. Teng, S. E. Street, L. Cerutti, S. M. Jane, J. A. Trapani, M. J. Smyth, et al. (2005)
Blood 106, 2995-3003
   Abstract »    Full Text »    PDF »
Free fatty acid release from human breast cancer tissue inhibits cytotoxic T-lymphocyte-mediated killing.
A. M. Kleinfeld and C. Okada (2005)
J. Lipid Res. 46, 1983-1990
   Abstract »    Full Text »    PDF »
Adoptive Cell Transfer Therapy Following Non-Myeloablative but Lymphodepleting Chemotherapy for the Treatment of Patients With Refractory Metastatic Melanoma.
M. E. Dudley, J. R. Wunderlich, J. C. Yang, R. M. Sherry, S. L. Topalian, N. P. Restifo, R. E. Royal, U. Kammula, D. E. White, S. A. Mavroukakis, et al. (2005)
J. Clin. Oncol. 23, 2346-2357
   Abstract »    Full Text »    PDF »
Activated Marrow-Infiltrating Lymphocytes Effectively Target Plasma Cells and Their Clonogenic Precursors.
K. Noonan, W. Matsui, P. Serafini, R. Carbley, G. Tan, J. Khalili, M. Bonyhadi, H. Levitsky, K. Whartenby, and I. Borrello (2005)
Cancer Res. 65, 2026-2034
   Abstract »    Full Text »    PDF »
Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes.
S. A. Rosenberg and M. E. Dudley (2004)
PNAS 101, 14639-14645
   Abstract »    Full Text »    PDF »
Dendritic Cells Strongly Boost the Antitumor Activity of Adoptively Transferred T Cells In vivo.
Y. Lou, G. Wang, G. Lizee, G. J. Kim, S. E. Finkelstein, C. Feng, N. P. Restifo, and P. Hwu (2004)
Cancer Res. 64, 6783-6790
   Abstract »    Full Text »    PDF »
Novel OK-432-conjugated Tumor Vaccines Induce Tumor-specific Immunity against Murine Tongue Cancer.
X. Li, H. Bukawa, M. Hirota, Y. Tsuyuki, S. Omura, and K. Fujita (2003)
Journal of Dental Research 82, 636-640
   Abstract »    Full Text »    PDF »
Induction of Human T Lymphocyte Cytotoxicity and Inhibition of Tumor Growth by Tumor-Specific Diabody-Based Molecules Secreted from Gene-Modified Bystander Cells.
B. Blanco, P. Holliger, R. G. Vile, and L. Alvarez-Vallina (2003)
J. Immunol. 171, 1070-1077
   Abstract »    Full Text »    PDF »
Identification of a Protein Fragment of Interleukin 2 Responsible for Vasopermeability.
A. L. Epstein, M. M. Mizokami, J. Li, P. Hu, and L. A. Khawli (2003)
J Natl Cancer Inst 95, 741-749
   Abstract »    Full Text »    PDF »
Phase II Trial of Autologous Tumor Vaccination, Anti-CD3-Activated Vaccine-Primed Lymphocytes, and Interleukin-2 in Stage IV Renal Cell Cancer.
A. E. Chang, Q. Li, G. Jiang, D. M. Sayre, T. M. Braun, and B. G. Redman (2003)
J. Clin. Oncol. 21, 884-890
   Abstract »    Full Text »    PDF »
TNF Plays an Essential Role in Tumor Regression after Adoptive Transfer of Perforin/IFN-{gamma} Double Knockout Effector T Cells.
C. H. Poehlein, H.-M. Hu, J. Yamada, I. Assmann, W. G. Alvord, W. J. Urba, and B. A. Fox (2003)
J. Immunol. 170, 2004-2013
   Abstract »    Full Text »    PDF »
Dendritic Cell-Based Vaccination in Solid Cancer.
A. Stift, J. Friedl, P. Dubsky, T. Bachleitner-Hofmann, G. Schueller, T. Zontsich, T. Benkoe, K. Radelbauer, C. Brostjan, R. Jakesz, et al. (2003)
J. Clin. Oncol. 21, 135-142
   Abstract »    Full Text »    PDF »
Interleukin 15 Promotes Antigen-independent in Vitro Expansion and Long-Term Survival of Antitumor Cytotoxic T Lymphocytes.
J. Lu, R. L. Giuntoli II, R. Omiya, H. Kobayashi, R. Kennedy, and E. Celis (2002)
Clin. Cancer Res. 8, 3877-3884
   Abstract »    Full Text »    PDF »
Rejection of Syngeneic Colon Carcinoma by CTLs Expressing Single-Chain Antibody Receptors Codelivering CD28 Costimulation.
N. M. Haynes, J. A. Trapani, M. W. L. Teng, J. T. Jackson, L. Cerruti, S. M. Jane, M. H. Kershaw, M. J. Smyth, and P. K. Darcy (2002)
J. Immunol. 169, 5780-5786
   Abstract »    Full Text »    PDF »
Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes.
M. E. Dudley, J. R. Wunderlich, P. F. Robbins, J. C. Yang, P. Hwu, D. J. Schwartzentruber, S. L. Topalian, R. Sherry, N. P. Restifo, A. M. Hubicki, et al. (2002)
Science 298, 850-854
   Abstract »    Full Text »    PDF »
Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors.
N. M. Haynes, J. A. Trapani, M. W. L. Teng, J. T. Jackson, L. Cerruti, S. M. Jane, M. H. Kershaw, M. J. Smyth, and P. K. Darcy (2002)
Blood 100, 3155-3163
   Abstract »    Full Text »    PDF »
Adoptive Immunotherapy of Advanced Tumors with CD62 L-Selectinlow Tumor-Sensitized T Lymphocytes Following Ex Vivo Hyperexpansion.
L.-X. Wang, B.-G. Chen, and G. E. Plautz (2002)
J. Immunol. 169, 3314-3320
   Abstract »    Full Text »    PDF »
Antimelanoma Activity of CTL Generated from Peripheral Blood Mononuclear Cells After Stimulation with Autologous Dendritic Cells Pulsed with Melanoma gp100 Peptide G209-2M Is Correlated to TCR Avidity.
S. Yang, G. P. Linette, S. Longerich, and F. G. Haluska (2002)
J. Immunol. 169, 531-539
   Abstract »    Full Text »    PDF »
Synergistic Enhancement of Antitumor Immunity with Adoptively Transferred Tumor-specific CD4+ and CD8+ T Cells and Intratumoral Lymphotactin Transgene Expression.
H. Huang, F. Li, J. R. Gordon, and J. Xiang (2002)
Cancer Res. 62, 2043-2051
   Abstract »    Full Text »    PDF »
Campbell De Morgan's 'Observations on cancer', and their relevance today.
J. M Grange, J. L Stanford, and C. A Stanford (2002)
J R Soc Med 95, 296-299
   Full Text »    PDF »
Sentinel Node Mapping Identifies Vaccine-Draining Lymph Nodes With Tumor-Specific Immunological Activity.
C. S. Chin and H. D. Bear (2002)
Ann. Surg. Oncol. 9, 94-103
   Abstract »    Full Text »    PDF »
Transduction of an IL-2 Gene into Human Melanoma-Reactive Lymphocytes Results in Their Continued Growth in the Absence of Exogenous IL-2 and Maintenance of Specific Antitumor Activity.
K. Liu and S. A. Rosenberg (2001)
J. Immunol. 167, 6356-6365
   Abstract »    Full Text »    PDF »
Tumor-Specific Tc1, But Not Tc2, Cells Deliver Protective Antitumor Immunity.
R. A. Kemp and F. Ronchese (2001)
J. Immunol. 167, 6497-6502
   Abstract »    Full Text »    PDF »
Augmentation Versus Inhibition: Effects of Conjunctional OX-40 Receptor Monoclonal Antibody and IL-2 Treatment on Adoptive Immunotherapy of Advanced Tumor.
J. Kjaergaard, L. Peng, P. A. Cohen, J. A. Drazba, A. D. Weinberg, and S. Shu (2001)
J. Immunol. 167, 6669-6677
   Abstract »    Full Text »    PDF »
Effects of Social Housing Condition on Chemotherapeutic Efficacy in a Shionogi Carcinoma (SC115) Mouse Tumor Model: Influences of Temporal Factors, Tumor Size, and Tumor Growth Rate.
L. R. Kerr, R. Hundal, W. A. Silva, J. T. Emerman, and J. Weinberg (2001)
Psychosom Med 63, 973-984
   Abstract »    Full Text »    PDF »
CD4+ T-Cell Immune Response to Large B-Cell Non-Hodgkin's Lymphoma Predicts Patient Outcome.
S. M. Ansell, M. Stenson, T. M. Habermann, D. F. Jelinek, and T. E. Witzig (2001)
J. Clin. Oncol. 19, 720-726
   Abstract »    Full Text »    PDF »
Locoregional Cellular Immunotherapy for Patients with Advanced Esophageal Cancer.
U. Toh, H. Yamana, S. Sueyoshi, T. Tanaka, F. Niiya, K. Katagiri, H. Fujita, K. Shirozou, and K. Itoh (2000)
Clin. Cancer Res. 6, 4663-4673
   Abstract »    Full Text »
Helper-Independent, L-Selectinlow CD8+ T Cells with Broad Anti-Tumor Efficacy Are Naturally Sensitized During Tumor Progression.
L. Peng, J. Kjaergaard, G. E. Plautz, D. E. Weng, S. Shu, and P. A. Cohen (2000)
J. Immunol. 165, 5738-5749
   Abstract »    Full Text »    PDF »
Divergent Roles for CD4+ T Cells in the Priming and Effector/Memory Phases of Adoptive Immunotherapy.
H.-M. Hu, H. Winter, W. J. Urba, and B. A. Fox (2000)
J. Immunol. 165, 4246-4253
   Abstract »    Full Text »    PDF »
Systemic Adoptive T-Cell Immunotherapy in Recurrent and Metastatic Carcinoma of the Head and Neck: A Phase 1 Study.
W. C. To, B. G. Wood, J. C. Krauss, M. Strome, R. M. Esclamado, P. Lavertu, D. Dasko, J. A. Kim, G. E. Plautz, B. E. Leff, et al. (2000)
Arch Otolaryngol Head Neck Surg 126, 1225-1231
   Abstract »    Full Text »    PDF »
Induction of Tumor Immunity by Removing CD25+CD4+ T Cells: A Common Basis Between Tumor Immunity and Autoimmunity.
J. Shimizu, S. Yamazaki, and S. Sakaguchi (1999)
J. Immunol. 163, 5211-5218
   Abstract »    Full Text »    PDF »
Tumor Infiltration by Adoptively Transferred T Cells Is Independent of Immunologic Specificity but Requires Down-Regulation of L-Selectin Expression.
J. Kjaergaard and S. Shu (1999)
J. Immunol. 163, 751-759
   Abstract »    Full Text »    PDF »
Cytotoxic T-Lymphocyte Epitope Immunodominance in the Control of Choroid Plexus Tumors in Simian Virus 40 Large T Antigen Transgenic Mice.
T. D. Schell, L. M. Mylin, I. Georgoff, A. K. Teresky, A. J. Levine, and S. S. Tevethia (1999)
J. Virol. 73, 5981-5993
   Abstract »    Full Text »
An Antigen-targeted Approach to Adoptive Transfer Therapy of Cancer.
D. Valmori, M. J. Pittet, D. Rimoldi, D. Lienard, R. Dunbar, V. Cerundolo, F. Lejeune, J.-C. Cerottini, and P. Romero (1999)
Cancer Res. 59, 2167-2173
   Abstract »    Full Text »    PDF »
Primary T-Cell and Activated Macrophage Response Associated with Tumor Protection Using Peptide/Poly-N-Acetyl Glucosamine Vaccination.
N. Maitre, J. M. Brown, M. Demcheva, J. R. Kelley, M. A. Lockett, J. Vournakis, and D. J. Cole (1999)
Clin. Cancer Res. 5, 1173-1182
   Abstract »    Full Text »    PDF »
Successful Adoptive Immunotherapy of Murine Poorly Immunogenic Tumor with Specific Effector Cells Generated from Gene-Modified Tumor-Primed Lymph Node Cells.
H. Tanaka, H. Yoshizawa, Y. Yamaguchi, K. Ito, H. Kagamu, E. Suzuki, F. Gejyo, H. Hamada, and M. Arakawa (1999)
J. Immunol. 162, 3574-3582
   Abstract »    Full Text »    PDF »
Immune surveillance against a solid tumor fails because of immunological ignorance.
A. F. Ochsenbein, P. Klenerman, U. Karrer, B. Ludewig, M. Pericin, H. Hengartner, and R. M. Zinkernagel (1999)
PNAS 96, 2233-2238
   Abstract »    Full Text »    PDF »
Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines.
K. Shimizu, R. C. Fields, M. Giedlin, and J. J. Mule (1999)
PNAS 96, 2268-2273
   Abstract »    Full Text »    PDF »
Stimulation of Tumors to Synthesize Tumor Necrosis Factor-{{alpha}} in Situ Using 5,6-Dimethylxanthenone-4-acetic Acid: A Novel Approach to Cancer Therapy.
W. R. Joseph, Z. Cao, K. G. Mountjoy, E. S. Marshall, B. C. Baguley, and L.-M. Ching (1999)
Cancer Res. 59, 633-638
   Abstract »    Full Text »    PDF »
Expanded Tumor-reactive CD4+ T-Cell Responses to Human Cancers Induced by Secondary Anti-CD3/Anti-CD28 Activation.
Q. Li, S. A. Furman, C. R. Bradford, and A. E. Chang (1999)
Clin. Cancer Res. 5, 461-469
   Abstract »    Full Text »    PDF »
Changes in the Fine Specificity of gp100(209-217)-Reactive T Cells in Patients Following Vaccination with a Peptide Modified at an HLA-A2.1 Anchor Residue.
T. M. Clay, M. C. Custer, M. D. McKee, M. Parkhurst, P. F. Robbins, K. Kerstann, J. Wunderlich, S. A. Rosenberg, and M. I. Nishimura (1999)
J. Immunol. 162, 1749-1755
   Abstract »    Full Text »    PDF »
Without Prior Stimulation, Tumor-associated Lymphocytes from Malignant Effusions Lyse Autologous Tumor Cells in the Presence of Bispecific Antibody HEA125xOKT3.
G. Strau{beta}, B. Guckel, D. Wallwiener, and G. Moldenhauer (1999)
Clin. Cancer Res. 5, 171-180
   Abstract »    Full Text »    PDF »
Tumor-Infiltrating Lymphocytes Exhibiting High Ex Vivo Cytolytic Activity Fail to Prevent Murine Melanoma Tumor Growth In Vivo.
A. Prevost-Blondel, C. Zimmermann, C. Stemmer, P. Kulmburg, F. M. Rosenthal, and H. Pircher (1998)
J. Immunol. 161, 2187-2194
   Abstract »    Full Text »    PDF »
Activation Requirements, Lytic Mechanism, and Development of a Novel Anti-CD8-Resistant CTL Population.
S. A. McCarthy, M. S. Mainwaring, D. S. Dougall, and E. S. Lamouse-Smith (1998)
J. Immunol. 160, 2715-2724
   Abstract »    Full Text »    PDF »
Successful Adoptive Cellular Immunotherapy Is Dependent on Induction of a Host Immune Response Triggered by Cytokine (IFN-{gamma} and Granulocyte/Macrophage Colony-Stimulating Factor) Producing Donor Tumor-Infiltrating Lymphocytes.
M. Nagoshi, P. S. Goedegebuure, U. L. Burger, N. Sadanaga, M. P. Chang, and T. J. Eberlein (1998)
J. Immunol. 160, 334-344
   Abstract »    Full Text »    PDF »
Tumor Immunology.
S. Shu, G. E. Plautz, J. C. Krauss, and A. E. Chang (1997)
JAMA 278, 1972-1981
   Abstract »    PDF »
Evidence for the Participation of Interleukin-2 (IL-2) and IL-4 in the Regulation of Autonomous Growth and Tumorigenesis of Transformed Cells of Lymphoid Origin.
M. R. Hassuneh, P. S. Nagarkatti, and M. Nagarkatti (1997)
Blood 89, 610-620
   Abstract »    Full Text »    PDF »
Topical Review: Gene Therapy for Neurologic Disease: Benchtop Discoveries to Bedside Applications. 1. The Bench.
B. L. Maria, C. D. Medina, K. B.N. Hoang, and M. I. Phillips (1997)
J Child Neurol 12, 1-12
   Abstract »    PDF »
Sensitization of Nude Mice Using Direct Liposome Transfer of Tumor Cell Antigens.
T. Ariyasu, O. Ike, S. Hitomi, H. Wada, Y. Okumura, and J. Sunamoto (1996)
Journal of Bioactive and Compatible Polymers 11, 191-202
   Abstract »
Interleukin-12 Synergizes With Interleukin-2 to Generate Lymphokine-Activated Killer Activity in Peripheral Blood Mononuclear Cells Cultured in Ovarian Cancer Ascitic Fluid.
D. P. J. Barton, D. K. Blanchard, C. Duan, W. S. Roberts, D. Cavanagh, S. DeCesare, and J. Y. Djeu (1995)
Reproductive Sciences 2, 762-771
   Abstract »    PDF »
Treatment of Metastatic Melanoma and Renal Cell Carcinoma With Interleukin-2.
L. A. Manson (1994)
JAMA 272, 1327
   Abstract »    PDF »
Immunobiologic Effects of Cytokine Gene Transfer of the B16-BL6 Melanoma.
S. E. Strome, J. C. Krauss, M. J. Cameron, K. Forslund, S. Shu, and A. E. Chang (1993)
Arch Otolaryngol Head Neck Surg 119, 1289-1295
   Abstract »    PDF »
Adoptive Cellular Therapy of Malignancy.
A. E. Chang, J. D. Geiger, V. K Sondak, and S. Shu (1993)
Arch Surg 128, 1281-1290
   Abstract »    PDF »
Gene Therapy for Cancer.
S. A. Rosenberg (1992)
JAMA 268, 2416-2419
   Abstract »    PDF »
Treatment of Human Melanoma Hepatic Metastases in Nude Mice With Human Cytotoxic T Lymphocytes.
N. J. Crowley, C. E. Vervaert, and H. F. Seigler (1991)
Arch Surg 126, 433-437
   Abstract »    PDF »
Enhanced Antitumor Reactivity of TumorSensitized T Cells by Interferon Alfa.
D. L. V. Woude, P. D. Wagner, S. Shu, and A. E. Chang (1991)
Arch Surg 126, 307-313
   Abstract »    PDF »
Patterns of Human Tumor-Infiltrating Lymphocytes in 120 Human Cancers.
C. M. Balch, L. B. Riley, Y. J. Bae, M. A. Salmeron, C. D. Platsoucas, A. von Eschenbach, and K. Itoh (1990)
Arch Surg 125, 200-205
   Abstract »    PDF »
Patterns of Relapse in 1001 Consecutive Patients With Melanoma Nodal Metastases.
A. Calabro, S. E. Singletary, and C. M. Balch (1989)
Arch Surg 124, 1051-1055
   Abstract »    PDF »
Production of Lymphokine-Activated Lymphocytes: Lysis of Human Head and Neck Squamous Cell Carcinoma Cell Lines.
D. M. Alessi, R. W. Hutcherson, and R. A. Mickel (1989)
Arch Otolaryngol Head Neck Surg 115, 725-730
   Abstract »    PDF »
Hepatectomy Prolongs Survival of Mice With Induced Liver Metastases.
M. H. Castillo, R. J. Doerr, N. Paolini Jr, S. Cohen, and M. Goldrosen (1989)
Arch Surg 124, 167-169
   Abstract »    PDF »
Natural Killer Activity of Lymphocytes Infiltrating Human Lung Cancers Following Preoperative Systemic Recombinant Interleukin 2.
T. M. Anderson, Y. Ibayashi, Y. Tokuda, S. Colquhoun, C. Holmes, and S. H. Golub (1987)
Arch Surg 122, 1446-1450
   Abstract »    PDF »



To Advertise     Find Products


Science. ISSN 0036-8075 (print), 1095-9203 (online)